Market Intelligence, Clinical Progress, and High-Purity Reagents for Multiple Myeloma and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PSMB5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PSMB5 (PS beta-5) WT & Mutant Recombinant Proteins (e.g., A49T, A50V resistance mutants). High purity (>95%), Endotoxin controlled. Sequence Verified. | View PSMB5 Products |
| Gene Delivery | PSMB5 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines and resistance profiling. | View PSMB5 Products |
| Benchmark Ab | Anti-PSMB5 Recombinant Antibody. Recombinant positive control for expression and Western Blot validation. | View PSMB5 Products |
| Validator | PSMB5 siRNA Set. For knockdown verification in functional assays. | View PSMB5 Products |
| Related Target A | PSMB8 (LMP7). Immunoproteasome subunit; essential for selectivity profiling to reduce off-target toxicity. | View PSMB8 Products |
| Related Target B | PSMB9 (LMP2). Immunoproteasome subunit; critical for comparative oncology and autoimmune disease assays. | View PSMB9 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Acquired Drug Resistance Profiling | Sequence-verified PSMB5 mutant proteins (A49T, A50V, Cys52Phe) available with >95% purity. |
| Selectivity Screening (Constitutive vs. Immunoproteasome) | Homolog panel proteins (PSMB5, PSMB8, PSMB9) strictly verified by mass spectrometry. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and recombinant controls included. |
| False Positives in Knockdown | Validated siRNA sets included for target specificity and survival assay checks. |
Live PSMB5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PSMB5 therapeutics is intensifying, with major players shifting focus from traditional peptide boronic acid inhibitors to non-covalent, reversible inhibitors and proteasome-targeting chimeras (PROTACs). As first- and second-generation therapies like Bortezomib and Carfilzomib face clinical hurdles due to acquired mutations, the next wave of R&D is targeting mutant PSMB5 variants and selective immunoproteasome subunits to bypass drug resistance and reduce peripheral neuropathy. Combination regimens targeting both the constitutive proteasome (PSMB5) and the immunoproteasome (PSMB8) represent a significant future trend to overcome acquired resistance and broaden clinical utility.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Covalent) | Takeda, Amgen, Onyx | Multiple Myeloma, Mantle Cell Lymphoma | Enzymatic Inhibition Assay (Need high-purity WT PSMB5) |
| Small Molecule (Non-Covalent) | Sanofi, Novartis, Academic Consortia, Biotech Startups | Solid Tumors, Resistant Myeloma, Relapsed/Refractory MM | Mutant Panel Profiling & Binding Kinetics (Need A49T/A50V Mutant Proteins and exact MW proteins) |
| Dual Inhibitor (PSMB5/8) | Onyx (Amgen), Celgene (BMS) | Autoimmune Diseases, Hematologic Malignancies | Selectivity Panel (Need PSMB5 & PSMB8 homolog panels) |
| PROTAC / Degrader | Arvinas, Kymera Therapeutics | Hematological Malignancies | Ubiquitination & Degradation Assays (Need Lentivirus for Stable Cell Lines) |
Related Target Recommendations
Beyond the core PSMB5 pathway, the following targets are crucial for combination therapy and selectivity profiling:
- CRBN (Cereblon) – Direct target of IMiDs (lenalidomide, pomalidomide). Essential for evaluating synergy with PSMB5 inhibitors in Multiple Myeloma combination therapy. (Product: View CRBN Products)
- CD38 / BCMA – Antibody targets for combination with proteasome inhibitors; useful for in vitro cell killing assays.
- PSMD1 – 19S regulatory particle subunit; relevant for PROTAC-mediated proteasome receptor recruitment studies.